Modulators of G-protein coupled receptors

US11535660B1 · kind B1 · utility

Assignee

• Cannot Therapeutics, Inc. · US

Inventors

• Johan Enquist · San Francisco, US
• Shyam Krishnan · Novato, US
• Suman Atwal · San Jose, US
• Daniel Erlanson · San Francisco, US
• Raymond V. Fucini · San Bruno, US
• Stig Hansen · Kensington, US
• Andrew Sawayama · San Francisco, US
• Steven Sethofer · Emeryville, US

Key dates

• Filing date: Mar 22, 2019
• Grant date: Dec 27, 2022
• Expiry date: Mar 22, 2039

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize or partially agonize or antagonize) glucagon?like peptide?1 receptor (“GLP?1R”) and/or the gastric inhibitory polypeptide receptor (“GIPR”). The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which modulation (e.g., agonism, partial agonism or antagonism) of GLP?1R and/or GIPR activities is beneficial for the treatment or prevention of the underlying pathology and/or symptoms and/or progression of the disease, disorder, or condition. In some embodiments, the modulation results in an enhancement of (e.g., an increase in) existing levels (e.g., normal or below normal levels) of GLP?1R and/or GIPR activity (e.g., signaling). In some embodiments, the chemical entities described herein further modulate (e.g., attenuate, uncouple)-arrestin signaling relative to what is observed with the native ligand. This disclosure also features compositions as well as other methods of using and making the said chemical entities.